Reducing regulatory intervention in system a priority: DCGI Raghuvanshi

Raghuvanshi, who was appointed to the top post in February this year, felt that regulation should be made more research centric

drugs, pharma, prices, drug prices, medicines, health
Press Trust of India Hyderabad
2 min read Last Updated : May 11 2023 | 5:29 PM IST

Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi on Thursday said bringing down regulatory intervention in the system and making it more simpler is a top priority for the organisation.

The DCGI is the apex authority in the country responsible for approval of licences of specified categories of drugs such as blood and blood products, intravenous fluids, vaccine and serum. It functions under the Directorate General of Health Services (DGHS) of the Ministry of Health.

Delivering a lecture at the CSIR-Indian Institute of Chemical Technology (IICT) here on the occasion of National Technology Day, he said there are currently many licences and interventions present in the system with a scope of making it much more simpler.

"...our (DCGI) current priorities for a couple of years, the first being, (we) want to reduce the regulatory intervention in the system. There are lot of licences and interventions. There is a scope of making it much more simpler. That is one area, where I have to work," he said.

Another priority area is to improve the subject experts committee where organisations like IICT can help in terms of bringing in new experts into the domain, he said.

Raghuvanshi, who was appointed to the top post in February this year, felt that regulation should be made more research centric.

Another priority area is to constantly keep increasing the footprint in digital space, he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :drugsregulation making

First Published: May 11 2023 | 5:29 PM IST

Next Story